Abstract
Development of molecular targeting agents, starting with imatinib for chronic myeloid leukemia or gefitinib for non-small cell lung cancer (NSCLC), has recently progressed at a rapid rate. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have already been developed to the 2nd and 3rd generation, and novel drug development targeted towards Met activation, which is an EGFR-TKI resistance mechanism, is ongoing. Although the era of new anticancer agents is moving towards an era of molecular targeting agents, the methods used for drug development are not different than before. In addition to the importance of pharmacokinetics (PK) and pharmacodynamics (PD) for drug development, emerging evidence is also demonstrating the significance of pharmacogenomics, since certain types of gene alteration may greatly affect drug metabolism, excretion, and notably, clinical efficacy. It is desirable to determine optimal doses of anticancer drugs by taking into account these factors that could potentially influence PK/PD. The following article reviews the clinical development of EGFR/Met inhibitors for NSCLC and the clinical pharmacology of these drugs.
Keywords: Epidermal growth factor receptor, Met, non-small cell lung cancer, pharmacology.
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Therapy
Current Drug Delivery
Related Books
Anthocyanins: Pharmacology and Nutraceutical Importance
Computer-Aided Drug Discovery Methods: A Brief Introduction
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Advanced Pharmacy
55
